Recombinant Mouse PD-L1 Protein (His Tag)

Supplier: Elabscience Product Name: Recombinant Mouse PD-L1 Protein (His Tag) Catalog No. PKSM040919 Product Type: recombinant protein Size: 200 ug Activity: Measured by its binding ability in a functional ELISA. Immobilized recombinant mouse PD1-L1 at 1 ?g/ml (100 ?l/well) can bind mouse PD1 with a linear range of 6.25-400 ng/ml. Protein Construction: A DNA sequence encoding the mouse CD274 (NP_068693.1) extracellular domain (Met 1-Thr 238) was fused with a polyhistidine tag at the C-terminus. Sequence: Met 1-Thr 238 Fusion Tag: C-His Accession: NP_068693.1 Species: Mouse Expressed Host: HEK293 Cells Shipping Conditions: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise. Purity: > 98 % as determined by SDS-PAGE Endotoxin: < 1.0 EU per ?g of the protein as determined by the LAL method Stability: Samples are stable for up to twelve months from date of receipt at -70?.Store it under sterile conditions at -20? to -80?. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. Molecular Weight: 26.3 kDa Applied MM: 40-45 kDa Formulation: Lyophilized from sterile PBS, pH 7.4 Reconstitution: Please refer to the printed manual for detailed information. Background: Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies   Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: IHC Antibodies   Immune Checkpoint Detection: ICC Antibodies   Immune Checkpoint Detection: FCM Antibodies   Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins   PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets Immunotherapy   Cancer Immunotherapy   Targeted Therapy